- GeoVax Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen Vaccine
- GeoVax Urges Immediate Action on Pandemic Preparedness as Biodefense Gaps Expose Fragile Supply Chains
- GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation
- GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology
- GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update
- GeoVax to Advance Gedeptin(R) into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results
- GeoVax to Report Second Quarter 2025 Financial Results and Provide Corporate Update on July 28, 2025
- GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine
- GeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand
- GeoVax to Present at the Emerging Growth Conference on July 16, 2025
- GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat
- GeoVax Responds to Growing Mpox Threat with Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives
- GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public Offering
- GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection
- GeoVax Comments on FDA Approval of Keytruda® in Head and Neck Cancer, Underscoring Potential for Gedeptin® Combination Therapy
- GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting
- GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA
- GeoVax to Participate in BIO International Convention 2025
- GeoVax Responds to WHO’s Fourth Declaration of Mpox as a Global Public Health Emergency
- GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients
- GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia
- GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology
- GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing
- GeoVax Commends FDA’s Shift to Risk-Based COVID-19 Vaccination Guidance
- GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation
- GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations
- GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025
- GeoVax Expands Gedeptin(R) Patent Portfolio
- GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production
- GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update
- GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting
- GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater
- GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress
- GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025
- GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations
- GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum
- GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates
- GeoVax to Present Clinical Data at Upcoming April Industry Events
- GeoVax to Present at the Emerging Growth Conference on April 16, 2025
- GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent
- GeoVax Reports 2024 Year-End Financial Results and Provides Business Update
- GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- GeoVax to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
- GeoVax Establishing Strategic Presence in Europe with Initial Footprint in the UK
- GeoVax to Present at the 37th Annual Roth Conference
- Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event “MPOX 2025: Navigating the Global Public Health Emergency” Featuring GeoVax CEO On March 6, 2025
- GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy
- GeoVax Response to WHO’s Third Declaration of Mpox as a Public Health Emergency of International Concern
- GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness
- Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification
